Biomérieux
Company Snapshot
Company Overview
bioMérieux focuses on diagnostic solutions (reagents, instruments, software and services) to determine the source of disease and contamination. The company plays a role in the biomarker landscape through its advanced diagnostic Vidas platforms. This platform offers immunoassays for key biomarkers like procalcitonin (PCT) and C-reactive protein (CRP), is used to diagnose and manage sepsis and bacterial infections. Its BioFire FilmArray panels integrate syndromic testing with pathogen and host biomarker detection for respiratory, gastrointestinal, and central nervous system infections. The company has also strengthened its oncology biomarker capabilities by acquiring bioTheranostics, whose breast cancer index (BCI) test guides treatment decisions in hormone receptor-positive breast cancer. bioMérieux is combating antimicrobial resistance by developing biomarker-based diagnostics that support targeted antibiotic use.
Financial Highlights (FY 2024)
This information is available for BCC Research members only.
Biomérieux In News
Company's Business Segments
- Clinical Applications : Immunoassays, Molecular biology, Microbiology, and Other ranges.
- Industrial Applications : Food and Pharma Quality Control
Applications/End User Industries
- Hospitals
- Laboratory
- Point Of Care
- Food Safety & Quality
- Pharma Quality Control
- Product Quality & Safety
- Customer Service
- Cybersecurity
